51-armata letter to shareholders

Armata Pharmaceuticals has addressed its shareholders with good news about how their company is progressing post-merger between C3J and AmpliPhi. The company also recently announced that it has received a Research and Development Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on R&D spending in Australia in 2018.